Company intelligence / Profile preview

Paratek Pharmaceuticals

Boston, Massachusetts, United Statesparatekpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Paratek Pharmaceuticals has successfully developed and commercialized Nuzyra® (omadacycline), a next-generation broad-spectrum antibiotic approved by the FDA for both oral and intravenous use in treating community-acquired bacterial pneumonia and acute bacterial skin infections. Clinical trials demonstrated efficacy against drug-resistant pathogens with favorable safety profiles. The company focuses on addressing antimicrobial resistance through innovative small molecule antibiotics targeting serious infectious diseases.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (notably tetracycline-class antibiotics)
Industry: Biotech

Drug pipeline

5 assets

omadacycline

Approved

4 more assets in the full pipeline.

Partnerships

Previously partnered with Novartis during early development stages; no major ongoing partnerships listed currently.

Beyond the preview

Go deeper on Paratek Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paratek Pharmaceuticals.